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Abstract: Current guidelines recommend initiation of a P2Y12 inhibitor for all patients with
non-ST-elevation acute coronary syndrome (NSTE-ACS) at the time of diagnosis (pre-treatment);
however, there are no randomized trials directly comparing pre-treatment with initiation at the
time of angiography to support this practice. We explore clinical and institutional parameters
potentially associated with benefit with this strategy in a decision-analytic model based on
available evidence from randomised trials. A decision analysis model was constructed comparing
three P2Y12 inhibitors in addition to aspirin in patients with NSTE-ACS. Based on clinical trial data,
the cumulative probability of 30 day mortality, myocardial infarction (MI) and major bleeding were
determined, and used to calculate the net clinical benefit (NCB) with and without pre-treatment.
Sensitivity analysis was performed to assess the relationship between NCB and baseline ischemic
risk, bleeding risk, time to angiography and local surgical revascularization rates. Pre-treatment with
ticagrelor and clopidogrel was associated with a greater than 50% likelihood of providing a >1%
increase in 30 day NCB when baseline estimated ischemic risk exceeds 11% and 14%, respectively.
Prasugrel pre-treatment did not achieve a greater than 50% probability of an increase in NCB
regardless of baseline ischemic risk. Institutional surgical revascularization rates and time to coronary
angiography did not correlate with the likelihood of benefit from P2Y12 pre-treatment. In conclusion,
pre-treatment with P2Y12 inhibition is unlikely to be beneficial to the majority of patients presenting
with NSTE-ACS. A tailored assessment of each patient’s individual ischemic and bleeding risk may
identify those likely to benefit.
Keywords: non-ST segment myocardial infarction; percutaneous coronary intervention;
cardiac catheterization and angiography
1. Introduction
Pre-treatment with anti-platelet agents, the co-administration of aspirin and a second agent
such as P2Y12 or glycoprotein IIb/IIIa inhibitors prior to coronary angiography in patients with
acute coronary syndromes without ST elevation, remains a complex and controversial topic in the
current era [1,2]. The rationale for pre-treatment includes decreasing ischemic events prior to coronary
angiography and a possible reduction in the risk of distal embolization and stent thrombosis during
PCI by allowing adequate time for greater platelet inhibition to occur prior to balloon-injury [3–5].
However, pre-treatment may increase bleeding risk prior to angiography, at the time of coronary
angiography during arterial puncture and sheath removal, and during cardiac surgery [3,6].
Withholding a second anti-platelet agent until the coronary anatomy is known may attenuate
the risk of bleeding among those ultimately receiving cardiac surgery; however, it does not afford the
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ischemic protection of these agents prior to coronary angiography and revascularization. Furthermore,
withholding pre-treatment prevents patients with an alternative diagnosis being over-treated and
exposing them to increased bleeding risks without any potential for ischemic protection.
The net benefit of pre-treatment is therefore a balance between a reduction in ischemic events
versus an increase in bleeding complications. This benefit may be modulated by specific patient
factors, such as individual ischemic and bleeding risk, as well as institutional factors. The factors
include the time delay to coronary angiography, which may increase the risk of ischemic events
prior to revascularization, and local propensity for coronary artery bypass grafting with associated
bleeding risks.
Many of the randomised clinical trials examining the efficacy of pre-treatment with P2Y12
inhibition are heterogeneous in their study populations, including patients with stable angina [7],
not scheduled for angiography [5], randomised after angiography [8], post fibrinolysis [9], and only
with ST-elevation acute coronary syndrome (STE-ACS) [10]. The ‘Comparison of Prasugrel at the Time
of Percutaneous Coronary Intervention (PCI) or as Pre-treatment at the Time of Diagnosis in Patients
with Non-ST Elevation Myocardial Infarction’ (ACCOAST) study is the only contemporary randomised
trial of the timing of administration of a second antiplatelet agent in patients with non-ST elevation
acute coronary syndromes [11]. The ACCOAST trial observed no ischemic benefit of pre-treatment
with prasugrel; however, an increase in major bleeding complications was demonstrated [11].
Due to the lack of randomised clinical trial evidence, current European Society of Cardiology (ESC)
guidelines are unable to recommend for or against pre-treatment with a P2Y12 inhibitor (in addition
to aspirin) for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) [12]. Given the
evidence gap in this area, we applied a decision-analytic model based on the available evidence from
randomised trials to explore the possible clinical and institutional factors that may be associated with
greater benefit with a pre-treatment strategy.
2. Experimental Section
2.1. Model Assumptions and Data Sources
We developed a decision-analytic model to explore the impact of pre-treatment with P2Y12
inhibitors administered at the time of initial NSTE-ACS diagnosis compared with administration at the
time of PCI in patients treated with a planned invasive management strategy. The model examined
the effects of death or myocardial infarction (MI), and major bleeding, as well as net clinical benefit
(i.e., combined death or MI and major bleeding events) within 30 days (Figure 1). Outcomes of the
model included the ischemic outcomes of death or recurrent myocardial infarction as a summation of
the estimated events prior to angiography, and then for each of the three treatment strategies (i.e., PCI,
CABG and medical management) up to 30 days, with bleeding events before and after angiography
similarly summated. To estimate the overall benefit of the strategy, we also report the net benefit
of pre-treatment with each of the P2Y12 inhibitors, calculated as the absolute reduction in a 30 day
ischemic event rate minus the absolute increase in bleeding event rate, (i.e., net clinical benefit (NCB))
between the pre-treatment and non-pre-treatment groups. For the purposes of this analysis, a clinically
significant benefit was defined as a ≥1% increase in NCB at 30 days. The clinical relevance of this can
be conceptualized as a Number Needed to Treat [NNT] of less than or equal to 100.
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Figure 1. Decision tree representing the outcomes in the Monte Carlo model during the 30 day cycle. 
DAPT=  Dual  anti‐platelet  therapy,  CABG  =  Coronary  artery  bypass  graft,  PCI  =  Percutaneous 
coronary intervention. 
2.2. Baseline Assumptions of Patient Risk 
Within this model, the baseline of death or MI within 30 days of diagnosis was set at 7% [13,14]. 
Half  of  this  risk  was  experienced  within  the  first  seven  days,  consistent  with  early  trials  of 
NSTE‐ACS where very  early angiography  (within 48 h) was not  commonplace.  [5] The  risk of a 
major  bleeding  event  within  30  days  was  estimated  to  be  2.5%,  again  with  half  of  the  risks 
experienced within the first seven days. [13,14]. These risks were converted to hourly risks in order 
to allow separate estimations for event rates before and after angiography. 
2.3. Procedural Rates, Timing and Impact on Risk 
The median time to angiography was set at 24 h, with the proportion of patients selected for 
surgical revascularization (CABG) initially set at 10%, and the medical management without PCI set 
at  30%,  with  the  remainder  of  the  patients  undergoing  PCI,  reflecting  rates  observed  in  local 
registries.  [13,14]  Revascularization  was  assumed  to  occur  without  subsequent  delay  and  any 
associated ischemic and bleeding events occurring between angiography and revascularization with 
each strategy was  included  in  the  risk associated with  that strategy. Among patients undergoing 
CABG, a relative risk reduction of death or MI by 30 days of 40% but a four‐fold increase in major 
bleeding events compared to medical management was assumed. Similarly, for patients undergoing 
PCI,  a  30%  relative  risk  reduction  in death  or MI  at  30 days, with  a  1.25‐fold  increase  in major 
bleeding, was assumed. 
Figure 1. Decision tree representing the outcomes in the Monte Carlo model during the 30 day
cycle. DAPT = Dual anti-platelet therapy, CABG = Coronary artery bypass graft, PCI = Percutaneous
coronary intervention.
2.2. Baseline Assumptions of Patient Risk
With n this model, the baseline of death or ays of diagno is wa set at 7% [13,14].
Half of this risk was experienced within the first seven days, consi tent with early trials of NSTE-ACS
where very early angiography (within 48 h) was not commonplace [5]. The risk of a major bleeding
event within 30 days was estimated to be 2.5%, again with half of the risks experienced within the first
seven days [13,14]. These risks were converted to hourly risks in order to allow separate estimations
for event rates before and after angiography.
2.3. Procedural Rates, Timing and Impact on Risk
The median time to angiography was set at 24 h, with the proportion of patients selected for surgical
revascularization (CABG) initially set at 10%, and the medical management without PCI set at 30%,
with the remainder of the patients undergoing PCI, reflecting rates observed in local registries [13,14].
Revascularization was assumed to occur without subsequent delay and any associated ischemic and
bleeding events occurring between angiography and revascularization with each strategy was included
in the risk associated with that strategy. Among patients undergoing CABG, a relative risk reduction of
death or MI by 30 days of 40% but a four-fold increase in major bleeding events compared to medical
management was assumed. Similarly, for patients undergoing PCI, a 30% relative risk reduction in
death or MI at 30 days, with a 1.25-fold increase in major bleeding, was assumed.
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2.4. Modification of Risks Associated with Initiation of P2Y12 Inhibition
The relative effect of clopidogrel pre-treatment versus placebo, ticagrelor versus clopidogrel, and
prasugrel versus clopidogrel were drawn from the results of the key large-scale randomized trials or
subsequent published subgroup analyses where available [3,4,11,15]. For base-case analysis, estimated
relative effects of death or MI, and major bleeding used the overall randomized trial findings, since
these provide the best estimates for treatment-related effects of each anti-platelet agent since they are
not subject to the usual limitations of subgroup analyses that apply to post-randomization sub-groups
(Table 1). When examining the effect of prasugrel, we use the results of ACCOAST in the base-case
since this was the only trial directly examining this question despite the fact that the TRITON TIMI 38
study was a much larger trial [3].
Table 1. Base case values used for decision analytic model on NSTE-ACS pretreatment.
Base Case Value(Confidence Interval) Reference
Baseline ischemic risk 7% [13,14]
Baseline bleeding risk 2.5% [13,14]
Delay to angiography 0–96 h
CABG rate 7%–15%
Clopidogrel effect on death/myocardial infarction rates 0.80 (0.72–0.90) [15]
Clopidogrel effect on bleeding rates 1.38 (1.13–1.67) [15]
Prasugrel vs. Clopidogrel on death/myocardial infarction rates 0.98 (0.78–1.23) [11]
0.81 (0.73-0.91) [3]
Prasugrel vs. Clopidogrel on bleeding rates 2.86 (1.44–5.68) [11]
1.32 (1.03–1.68) [3]
Ticagrelor vs. Clopidogrel on death/myocardial infarction rates 0.83 (0.74–0.93) [4]
Ticagrelor vs. Clopidogrel on bleeding rates 1.03 (0.93–1.15) [4]
2.5. Sensitivity Analysis
To provide estimates of potential risks and benefits, 10,000 runs of the model were undertaken
with bleeding events, ischemic events, and the NCB for each agent was calculated for each run.
The proportion of scenarios where the net clinical benefit or net mortality benefit was positive
relative to the comparator for each of the literature-based therapy comparisons (clopidogrel versus
placebo, prasugrel versus clopidogrel, and ticagrelor versus clopidogrel) was summed and reported as
a percentage. These estimates were then used to calculate the relative effect of ticagrelor and prasugrel
over placebo and reported similarly. In order to quantify the magnitude of potential benefit, the
absolute differences in the overall 30 day rate of ischemic events and bleeding events associated with
pre-treatment compared with no pre-treatment were used to calculate the number needed to treat
(NNT) for each run of the model.
The treatment effects associated with each of the P2Y12 inhibitors was allowed to vary across the
range of the reported 95% confidence bounds for both death or MI and major bleeding. However, due to
the differences in reported bleeding events associated with both ticagrelor and prasugrel, the bleeding
risk associated with the proportion of patients undergoing CABG were modeled separately using
relative hazards that differed from the overall population. For all of these analyses, P2Y12 inhibition
was considered not to have any effect on peri-operative ischemic events.
To explore the relationship between varying degrees of baseline ischemic and bleeding risk,
time to angiography, institutional rates of CABG and medical management, and treatment effects
associated with the specific therapies, multi-way sensitivity analysis was employed. Within each
iteration of the model, baseline ischemic risk was allowed to randomly vary between 0% and 15%,
while the risk of major bleeding was varied between 0% and 6% with 70% of this variation linked to
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the ischemic risk given the strong correlation between ischemic and bleeding risks observed among
individual patients clinically. Again, with half the 30 day risk experienced within the first seven days,
both the bleeding and ischemic risks were converted to an hourly risk.
The time to angiography was allowed to vary randomly between 0 and 96 h, while the proportion
of patients deemed appropriate for CABG and medical management were varied between 7% and
15%, and 35%–45%, respectively. However, recognizing that patients with an increased ischemic risk
were more likely to undergo CABG rather than PCI, the likelihood of CABG was adjusted by a factor
of 1.25 in those with an increased ischemic risk and 0.5 for those models with an ischemic risk of <5%.
Therefore, a CABG rate of 10% was increased to 12.5% if ischemic risk was >7%.
The relationship between the likely NCB rates and the estimates of the NNT with varying degrees
of: ischemic risk; bleeding risk; time to angiography; and the local surgical revascularization rate
were explored. The number needed to harm (NNH) was calculated as 100/absolute event increase %.
All models were constructed in STATA 14.0 (Manufacturer, College Station, TX, USA).
3. Results
A routine pre-treatment strategy was modelled, and the outcomes can be seen in Table 2. Overall,
in this base case, there was no net clinical benefit for pre-treatment with any P2Y12 inhibitor with NNH
varying from 22 to 500 with prasugrel and ticagrelor respectively.
Table 2. Base case modeled with an untreated baseline ischemic risk of 7% and a bleeding risk of 2.5%.
No Pre-Treatment
(at 30 Days) P2Y12
Inhibitor
Pre-Treatment Risk (at 30 Days)
Death
or MI
Major
Bleeding
Death or
MI
Major
Bleeding
ARR
(Death or MI)
ARI
(Major Bleeding) NCB NNH
6.3% 3.5%
Clopidogrel 5.1% 4.9% 1.2% 1.4% −0.2% 500
Prasugrel 5.1% 9.2% 1.2% 5.7% −4.5% 22
Ticagrelor 4.2% 6.8% 2.1% 3.3% −1.2% 83
ARR: Absolute risk reduction; ARI: Absolute risk increase; NNH: Number needed to harm; NCB: Net clinical
benefit (calculated as absolute risk reduction in ischemic events minus the absolute increase in bleeding
event rates).
3.1. Sensitivity Analysis
A one- and two-way sensitivity analyses was performed for each of the following variables
assuming a range of plausible values: (1) estimated ischemic risk; (2) estimated major bleeding risk;
(3) institutional CABG rate and (4) time to angiography.
3.2. Increase in Net Clinical Benefit (NCB) with Pre-Treatment
Pre-treatment with P2Y12 inhibition had a variable likelihood of achieving a positive net clinical
benefits (NCB) depending on the agent used and the patient’s level ischemic and bleeding risk.
Figure 2A–C display the likelihoods of achieving a positive NCB for each of the three anti-platelets
agents at varying levels of ischemic risk, with 30 day bleeding risk plotted for values between 0%
and 5%. With all three agents, increasing levels of ischemic risk resulted in a higher likelihood of
achieving a positive NCB. However, the likelihood was strongly modulated by bleeding risk. As seen
with clopidogrel, patients with a baseline ischemic risk of 6% and a 30 day bleeding risk of 0% had
an 82% likelihood of achieving a positive NCB. However, when the 30 day bleeding risk increased
to 5%, those with a 6% baseline ischemic risk had only a 15% likelihood of achieving a positive NCB.
A similar trend was seen with ticagrelor, where patients with a 5% bleeding risk only reached a 50%
likelihood of achieving a positive NCB at a baseline ischemic risk of 18%.
J. Clin. Med. 2016, 5, 72 6 of 12J. Clin. Med. 2016, 5, 72  6 of 12 
 
 
Figure  2.  Estimated  probability  of  achieving  a  positive  30  day Net Clinical  Benefit  (NCB)  from 
pre‐treatment with  (A)  clopidogrel;  (B)  ticagrelor  and  (C) prasugrel  at varying  levels of  baseline 
ischemic and bleeding risk. 
Importantly, a greater than 50% likelihood of achieving a positive NCB was only reached with 
clopidogrel and  ticagrelor. Prasugrel was associated with  low  likelihoods of achieving a positive 
NCB, at all levels of ischemic and bleeding risk. Even using estimates of efficacy and safety from the 
TRITON TIMI 38 study for prasugrel suggests low likelihoods of a positive NCB due to the higher 
rates of bleeding with this agent (data not shown). 
Figure  3  further  describes  the  relationship  between  achieving  a  positive  NCB  from 
pre‐treatment based on a patient’s estimated 30 day risk of death or myocardial infarction (ischemic 
risk) compared with their estimated 30 day risk of major bleeding (bleeding risk). Points below the line 
delineate baseline ischemic and bleeding profiles being associated with a 50% or more likelihood of 
achieving  a  positive  NCB  with  pre‐treatment.  At  low  levels  of  ischemic  risk,  both  agents  were 
associated  with  benefits  where  the  bleeding  risk  remained  very  low.  However,  as  ischemic  risk 
increased, a benefit was only found if the estimated bleeding risk remained below the line of intersection 
for each agent. Due  to  the greater  ischemic benefit associated with  ticagrelor, a greater  tolerance  for 
Figure 2. Estimated probability of ac ie i a sitive 30 day Net Clinical Benefit (NCB) from
pre-treatment with (A) clopidogrel; (B) tica l ( ) rasugrel at varying levels of baseline
ischemic and bleeding risk.
Importantly, a greater than 50% likelihood of achieving a positive NCB was only reached with
clopidogrel and ticagrelor. Prasugrel was associated with low likelihoods of achieving a positive NCB,
at all levels of ischemic and bleeding risk. Even using estimates of efficacy and safety from the TRITON
TIMI 38 study for prasugrel suggests low likelihoods of a positive NCB due to the higher rates of
bleeding with this agent (data not shown).
Figure 3 further describes the relationship between achieving a positive NCB from pre-treatment
based on a patient’s estimated 30 day risk of death or myocardial infarction (ischemic risk) compared
with their estimated 30 day risk of major bleeding (bleeding risk). Points below the line delineate
baseline ischemic and bleeding profiles being associated with a 50% or ore likelihood of achieving
a positive NCB with pre-treatment. At low levels of ischemic risk, both agents were associated with
benefits where the bleeding risk remained very low. However, as ischemic risk increased, a ben fit was
only found if the estimated bleeding risk remained below th line of inters ction for each agent. Due to
the greater ischemic benefit associated with ticagrelor, a greater tolerance for baseline bleeding risk
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is observed. With regards to prasugrel, harm from treatment was found with all levels of estimated
30 day ischemic risk, except in patients with the lowest bleeding risk (estimated 30 day bleeding
risk <1%).
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Figure 3. Frontier plot with each  line  representing  the estimates of 30 day Net Clinical Benefit at 
varying levels of baseline ischemic and bleeding risk for clopidogrel, ticagrelor and prasugrel. Area 
below each line indicates a neutral or positive net clinical benefit from pre‐treatment. Using this plot 
and assuming a 4% 30 day risk of major bleeding, pre‐treatment is harmful with any P2Y12 inhibitor 
at 2% 30 day  ischemic  risk  (Point A), beneficial with clopidogrel only at 8% 30 day  ischemic  risk 
(Point B), and beneficial with both ticagrelor and clopidogrel at 13% 30 day ischemic risk (Point C). 
3.3. Time to Coronary Angiography and Institutional CABG Rate 
There was  no  correlation  between  the  time  to  angiography  and  benefits with  a  strategy  of 
pre‐treatment with any of the three P2Y12 regardless of a patient’s ischemic and bleeding risk. 
Overall, variability in the institutional CABG rate had a minimal effect on providing an overall 
benefit with pre‐treatment with each of the three agents. 
3.4. Magnitude of Effect: The Likelihood Providing a Significant Clinical Benefit from Pre‐Treatment 
As  patients’  ischemic  risk  increased,  there was  a  higher  likelihood  that  pre‐treatment with 
either ticagrelor and clopidogrel would achieve a significant clinical benefit defined as a 1% increase 
in NCB  at  30  day  (Figure  4). Hence,  pre‐treatment with  clopidogrel  in  a  patient with  a  30  day 
ischemic  risk  of  3%  had  less  than  3%  likelihood  of  a  achieving  a  significant  clinical  benefit. This 
likelihood rose to 60% among those with a 30 day ischemic risk of 18%. Similarly, with ticagrelor, a 
patient with a 30 day ischemic risk of 3% had only approximately 5% likelihood of providing at least 
a 1% increase in NCB; however, this increases to 68% with an ischemic risk of 18%. Pre‐treatment 
with prasugrel was associated with very  low  likelihoods of achieving significant clinical benefits, 
even in patients with a high ischemic risk. 
Figure 3. Frontier plot with each line representing the estimates of 30 day Net Clinical Benefit at varying
levels of baseline ischemic and bleeding risk for clopidogrel, ticagrelor and prasugrel. Area below
each line indicates a neutral or positive net clinical benefit from pre-treatment. Using this plot and
assuming a 4% 30 day risk of major bleeding, pre-treatment is harmful with any P2Y12 inhibitor at
2% 30 day ischemic risk (Point A), beneficial with clopidogrel only at 8% 30 day ischemic risk (Point B),
and beneficial with both ticagrelor and clopidogrel at 13% 30 day ischemic risk (Point C).
3.3. Time to Coronary Angiography and Institutional CABG Rate
There was no correlation between the time to angiography and benefits with a strategy of
pre-treatment with any of the three P2Y12 regardless of a patient’s ischemic and bleeding risk.
Overall, variability in the institutional CABG rate had a minimal effect on providing an overall
benefit with pre-treatment with each of the three agents.
3.4. Magnitude of Effect: The Likelihood Providing a Significant Clinical Benefit from Pre-Treatment
As patients’ ischemic risk increased, there was a higher likelihood that pre-treatment with either
ticagrelor and clopidogrel would achieve a significant clinical benefit defined as a 1% increase in NCB
at 30 day (Figure 4). Hence, pre- reatment with clopidogrel in a patient with a 30 day ischemic risk
of 3% had less than 3% likelihood of a ac ievi g signific nt clinical benefit. This likelihood rose
to 60% among those with a 30 day ischemic risk of 18%. Similarly, with ticagrelor, a patient with
a 30 day ischemic risk of 3% had only approximately 5% likelihood of providing at least a 1% increase
in NCB; however, this increases to 68% with an ischemic risk of 18%. Pre-treatment with prasugrel was
associated with very low likelihoods of achieving significant clinical benefits, even in patients with
a high ischemic risk.
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Figure  4.  Estimated  likelihood  of  deriving  a  significant  clinical  benefit  from  pre‐treatment with 
clopidogrel, ticagrelor and prasugrel at varying levels of baseline ischemic risk. Significant clinically 
benefit defined as absolute increase in 30 day Net Clinical Benefit by 1% or more (NNT < 100). 
4. Discussion 
Major society guidelines either support the use of pre‐treatment in patients with acute coronary 
syndromes or refrain from advising on pre‐treatment due to the lack of support from clinical trial 
data [12,16]. ACCOAST, a contemporary randomized clinical trial assessing prasugrel pre‐treatment 
in NSTE‐ACS, was unable to demonstrate a reduction of ischemic outcomes [11]. We built a decision 
analysis model  for  the  clinical utility of pre‐treatment based on  the  relative  risk  reductions  from 
major  clinical  trials  on  the  currently  recommended  dual  anti‐platelet  agents  [5,7–9,11].  The 
likelihood  of  providing  a  substantial  benefit with  pre‐treatment  (NNT  <  100) was  not  observed 
unless the baseline ischemic risk exceeded 11% and 14% for ticagrelor and clopidogrel, respectively. 
It  should  be  noted  that  these  estimates  are  sensitive  to  the  baseline  risk  of  bleeding,  and  since 
clopidogrel was modelled with less impact on bleeding, this allows for a greater tolerance of baseline 
bleeding risk using this agent. Institutional characteristics of time to angiography were not associated 
with increased net clinical benefit and institutional CABG rates had only minimal effects on net clinical 
benefit with  pre‐treatment  using  each  of  the  agents.  This  analysis  suggests  that  a  pre‐treatment 
strategy with P2Y12 inhibitors is confined only to patients at relatively high predicted ischemic risk. 
Consequently, decisions  to  initiate pre‐treatment  should be dependent on careful and potentially 
objective evaluation of  ischemic and bleeding risk. This can be done easily at  the patient bedside 
with well‐validated  risk  scores  such  as  the Global Registry  of Acute Coronary Events  (GRACE) 
score. 
Large‐scale  randomized  studies of  intravenous glycoprotein  IIb/IIIa  inhibition given “upstream” 
before  coronary  angiography  in  NSTE‐ACS  have  failed  to  demonstrate  a  significant  reduction  in 
ischemic  events  when  compared  with  these  agents  used  in  the  peri‐procedural  setting  [17,18]. 
Pre‐treatment with P2Y12 inhibition in NSTE‐ACS remains controversial because much of the evidence 
supporting  its practice  is derived  from  trials which  included patients with stable angina, STE‐ACS, 
and  those  having  received  fibrinolysis  for  STE‐ACS  [7–11]. Data  from  small  observational  studies 
suggest reductions in peri‐procedural ischemic events associated with pre‐treatment with clopidogrel, 
with  similar  incremental benefits observed with  large  loading doses  compared with  small  loading 
doses  of  this  agent,  but  these  analyses  are  confined  to  those  actually  receiving  PCI  [7,19–22].  In 
Figure 4. Estimated likeli f i i i ificant clinical benefit from pre-treatment with
clopidogrel, ticagrelor and prasugrel at r i l ls f seline ischemic risk. Significant clinically
benefit defined as absolute increase in 30 day et li ical e efit 1 or more (NNT < 100).
4. Discussion
Major society guidelines either support the use of pre-treatment in patients with acute coronary
syndromes or refrain from advising on pre-treatment due to the lack of support from clinical trial
data [12,16]. ACCOAST, a contemporary randomized clinical trial assessing prasugrel pre-treatment
in NSTE-ACS, was unable to demonstrate a reduction of ischemic outcomes [11]. We built a decision
analysis model for the clinical utility of pre-treatment based on the relative risk reductions from major
clinical trials on the currently recommended dual anti-platelet agents [5,7–9,11]. The likelihood of
providing a substantial benefit with pre-treatment (NNT < 100) was not observed unless the baseline
ischemic risk exceeded 11% and 14% for ticagrelor and clopidogrel, respectively. It should be noted that
these estimates are sensitive to the baseline risk of bleeding, and since clopidogrel was modelled with
less impact on bleeding, this allows for a greater tolerance of baseline bleeding risk using this agent.
Institutional characteristics of time to angiography were not associated with increased net clinical
benefit and institutional CABG rates had nly minimal effects on net clinical benefit with pre-treatment
using ach of the agents. This analysis suggests that a pre-treatment strategy with P2Y12 inh bitors is
confi ed only to pat ents a relatively high predicted ischemic risk. Co sequently, decisions to initiate
pre-treatment should be dep ndent on careful and potentially objective evaluation of ischemic and
bleeding risk. This can be done ea ily at the patient bedside with well-validated isk scores such as the
Global Registry of Acute Coronary Events (GRACE) score.
Large-scale randomized studies of intra e o s l co rotein IIb/IIIa inhibition given “upstream”
before coronary angiography in STE-ACS have failed to demonstrate a significant reduction
in ischemic events when compared with these agents used in the peri-procedural setting [17,18].
Pre-treatment with P2Y12 inhibition in NSTE-ACS remains controversial because much of the evidence
supporting its practice is derived from trials which included patients with stable angina, STE-ACS,
and those having received fibrinolysis for STE-ACS [7–11]. Data from small observational studies
suggest reductions in peri-procedural ischemic events associated with pre-treatment with clopidogrel,
with similar incremental benefits observed with large loading doses compared with small loading
doses of this agent, but these analyses are confined to those actually receiving PCI [7,19–22]. In contrast,
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the first randomized comparison of this question, Clopidogrel for the Reduction of Events during
Observations (CREDO) study [8] included patients who were planned for PCI (and therefore included
elective patients), and the PerCutaneous Intervention-CLopidogrel as Adjunctive ReperfusIon TherapY
(PCI-CLARITY) trial [9] included only those with ST elevation who had received thrombolysis.
A sub-study of the large Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial [15]
reported a median time from randomisation to angiography was 10 days, making direct comparisons
to the modern era where time to angiography is generally less than 48 h, less reliable. However, the
patient population in CURE only included those with acute coronary syndromes without ST elevation,
and therefore represented the specific group of interest for this discussion [5].
Several meta-analyses attempting to address this question have included these studies, and have
reported a benefit of pre-treatment with clopidogrel in PCI patients [20,23,24]. This was demonstrated
in the 2012 meta-analysis of 37,814 patients by the Action group, which showed a statistically
significant reduction in major cardiac events (9.83% versus 12.35% p < 0.001) in those pre-treated with
clopidogrel [20]. This study also found no significant difference in mortality with pre-treatment and no
significant association between pre-treatment and major bleeding [20]. However, these studies have
focused on the subgroup of patients who actually received PCI, and excluded those who underwent
coronary artery bypass grafting or continued medical management. Hence, these meta-analyses focus
on the group of patients who are likely to have the most favourable balance between ischemic benefit
and bleeding risk. In contrast, a meta-analysis of patients undergoing coronary artery bypass grafting
from both observational and randomized studies demonstrates a clear increase in bleeding events with
an increase in mortality among these patients [6]. In a meta-analysis of three randomised trials and
17 observational studies, Biancari et al. demonstrated that pre-operative exposure to clopidogrel was
associated with an increased risk of death (RR: 1.3; CI: 1.02–1.67), re-operation for bleeding (RR: 1.88;
CI: 1.37–2.58) and need for packed red blood cells (RR: 1.23; CI: 1.10–1.37) [6].
ACCOAST is the only other randomized control trial of pre-treatment in ACS patients without ST
elevation. This study compared a half load of prasugrel as pre-treatment with a further half dose after
the coronary anatomy had been identified by angiography versus 60 mg of prasugrel post-angiography
among those undergoing PCI, with mean time from pre-treatment to coronary angiogram times of
4 h [11]. PCI was performed in 69% of patients, CABG in 6.2%, and medical management in 25%.
Pre-treatment did not reduce ischemic outcomes of NSTE-ACS; however, it resulted in increased
bleeding events [11]. As a result of this trial, the ESC guidelines caution against pre-treatment with
prasugrel; however, they are unable to advise for or against pre-treatment with other P2Y12 inhibition
in the management of NSTE-ACS [12]. It is worth mentioning that ticagrelor pre-treatment was studied
in the randomized control trial, “Administration of Ticagrelor in the Cath Lab or in the Ambulance for
New ST Elevation Myocardial Infarction to Open the Coronary Artery” (ATLANTIC) among patients
with STE-ACS, and resulted in no reduction in the composite end point of death, myocardial infarction,
stroke, urgent revascularization or stent thrombosis, though a very short time difference in dosing
times between the two arms (i.e., 31 min) occurred in this study [10].
Based on our analysis, pre-treatment with ticagrelor or clopidogrel is anticipated to be of benefit
in specific populations of patients presenting with NSTE-ACS, particularly those with a high risk
of ischemic events. Pre-treatment with ticagrelor and clopidogrel could result in a greater than
50% probability of achieving a positive 30 day NCB at lower levels of individual bleeding risk
combined with higher baseline ischemic risk. This emphasises the need for the clinician to be able
to accurately identify a patient’s ischemic risk using well-validated tools such as the GRACE risk
scoring system. For example, a GRACE score of approximately 150 translates to an ischemic risk
of >11%, representing the threshold for ticagrelor pretreatment [25]. Hence, while the validity of
internationally derived risk scores requires local calibration, this risk-score threshold based decision
is analogous to using the CHA2DS2-VASc score for identifying patients at sufficient stroke risk
warranting anticoagulation in non-valvular AF. Nevertheless, prospective confirmation of pretreatment
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thresholds is desirable, and future studies of pretreatment should clearly stratify patients by baseline
ischemic and bleeding risk.
Given the greater levels of platelet inhibition, ticagrelor was associated with an increase in NCB
at lower thresholds of ischemic risk than observed with clopidogrel. However, among patients with
the highest bleeding rates (5%), ticagrelor pre-treatment was only beneficial when the ischemic risk
exceeded 18%. Conversely, in the same high risk bleeding population, clopidogrel pre-treatment
required an ischemic risk of only 16% in order to obtain a greater than 50% probability of achieving
a positive 30 day NCB.
Limitations
Given the paucity of clinical trial data specifically addressing the question of pre-treatment
in patients with NSTE-ACS, this decision-making analysis relies upon assumptions from numerous
clinical trials. Firstly, the initial assumptions for clopidogrel are based on the CURE trial, which reflected
clinical practice of over a decade ago, before the introduction of radial arterial access, longer delays
to angiography, less refined coronary stent technology and less adjunctive anti-ischemic therapies
available [5]. The net effect of the aforementioned differences may in fact be an overestimation of the
ischemic benefit of pre-treatment, as suggested in a recent meta-analysis in which a modest effect of
major cardiovascular events was noted in older randomized control trials such as CURE, but was
not found in more recent studies [5,23]. Hence, our analysis may well over estimate the benefits of
pre-treatment with clopidogrel and then, consequently, the newer P2Y12 agents. For the purposes of
the decision-making analysis, the model assumes therapeutic efficacy at the time of administration of
the P2Y12 inhibitor. In the clinical setting, there would be a delay prior to peak therapeutic efficacy
with the time dependent on the P2Y12 inhibitor employed.
Secondary, the pre-treatment effects of ticagrelor were modelled on the PLATO trial, which did
not formally examine pre-treatment of this agent [4]. Nevertheless, it offers the best available evidence
for the pre-angiography use of ticagrelor compared with clopidogrel in the NSTE-ACS population.
This analysis does not take into account patients with presumed NSTE-ACS who go on to have
normal coronaries with an alternative diagnosis such as myocarditis. Given these patients do not
proceed to PCI or CABG, the absolute effect on their ischemic benefit or bleeding complication rate is
likely to be negligible. Again, as a consequence, actual benefits of pre-treatment in real world practice
may be less striking than what is presented in this decision-analytic model.
5. Conclusions
Decision analysis using treatment effects observed in randomized clinical trials, across plausible
ranges of ischemic and bleeding risk suggests that pre-treatment may only benefit patients with
NSTE-ACS with a very high ischemic risk, and the practice of routine use may be harmful.
The magnitude of this benefit is likely to benefit those in the subgroups of patients at a low risk of
bleeding and is likely to be small. Further analysis with an appropriately powered randomised control
trial would help clarify this issue but will be challenging given the very small effect expected from
pre-treatment. This decision- analysis model is not sufficient to warrant a change in current guidelines
for the management of NSTE-ACS; however, it highlights the need for controlled trials assessing
the benefits of pre-treatment with P2Y12 inhibitors, ticagrelor and clopidogrel, with randomization
stratified by objective measures of ischaemic and bleeding risk.
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